<DOC>
	<DOCNO>NCT01684215</DOCNO>
	<brief_summary>This study comprise two portion : Phase 1 portion Phase 2 portion . The Phase 1 portion single-country , non-randomized , open label , clinical trial evaluate safety , tolerability , preliminary efficacy , PK profile PD-0332991 single agent Japanese patient advance solid tumor , PD-0332991 combination letrozole first-line treatment Japanese patient ER ( + ) HER2 ( - ) ABC . The Phase 2 portion single-country , non-randomized , open-label , single-cohort , multi-center clinical trial evaluate efficacy safety PD-0332991 combination letrozole first-line treatment postmenopausal Japanese patient ER ( + ) HER2 ( - ) ABC .</brief_summary>
	<brief_title>A Study Of Oral Palbociclib ( PD-0332991 ) , A CDK4/6 Inhibitor , As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER ( + ) HER2 ( - ) Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Phase 1 In Part 1 , advance solid tumor ( except SCLC retinoblastoma ) proven histologically cytologically original diagnosis , refractory standard therapy standard care therapy available . In Part 2 Phase 2 , post menopausal woman proven diagnosis ERpositive , HER2negative adenocarcinoma breast evidence locoregionally recurrent metastatic disease ( include bone disease ) amenable resection radiation therapy curative intent chemotherapy clinically indicate . Adequate blood cell count , kidney function liver function Eastern Cooperative Oncology Group [ ECOG ] score 0 1 . Resolved acute effect prior therapy baseline severity Grade ≤1 Phase 2 Adult woman ( ≥ 20 year age ) proven diagnosis adenocarcinoma breast evidence locoregionally recurrent metastatic disease amenable resection radiation therapy curative intent chemotherapy clinically indicate . Documentation histologically cytologically confirm diagnosis ER ( + ) breast cancer base local laboratory result . Adequate blood cell count , kidney function liver function Eastern Cooperative Oncology Group [ ECOG ] score 0 2 . Phase 1 Active uncontrolled symptomatic CNS metastasis . Uncontrolled infection , unstable sever intercurrent medical condition , current drug alcohol abuse Active unstable cardiac disease history heart attack within 6 month Phase 2 HER2 positive tumor base local laboratory result utilize one sponsor approve assay . Known active uncontrolled symptomatic CNS metastasis , carcinomatous meningitis , leptomeningeal disease . Prior neoadjuvant adjuvant treatment non steroidal aromatase inhibitor ( ie , anastrozole letrozole ) disease recurrence within 12 month complete treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Phase 1/2</keyword>
	<keyword>PD-0332991</keyword>
	<keyword>palbociclib</keyword>
	<keyword>Cyclin Dependent Kinase 4/6 inhibitor</keyword>
	<keyword>Japanese</keyword>
	<keyword>solid tumor</keyword>
	<keyword>breast cancer</keyword>
	<keyword>A5481010</keyword>
</DOC>